One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices

References

• Smolen JS, Aletaha D, BiJsma JWJ, Breedveld FC, Boumpas D, Burmester GB, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Van Der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde DM, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceeding the period of radiographic assessment. Arthritis Rheum. 2009;60:1242–9.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints Arthritis Rheum. 2011;63:3702–11.
   PubMed Web of Science ®Google Scholar
• Katayama K, Okubo T, Sato T, Ito H, Fukai R, Baba H. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. Mod Rheumatol. 2015;25:50–5.
   PubMed Web of Science ®Google Scholar
• Van der Heijde DM, van’t Hof MA, van Riel Pl, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916–20.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smallen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness validity in the rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100–8.
   Web of Science ®Google Scholar
• Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of American college of rheumatology/European league against rheumatism 2011 remission criteria. Arthritis Rheum. 2011;63:3204–15.
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64:640–7.
   PubMed Web of Science ®Google Scholar
• Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the 3 core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American college of rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48:625–30.
   PubMed Web of Science ®Google Scholar
• Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol. 2005;32:1432–9.
   PubMed Web of Science ®Google Scholar
• Pincus T, Bergman MJ, Yazici Y. RAPID3-An index of physical function, pain, and grovel status as “vital signs’’ to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis. 2009;67:211–25.
   PubMedGoogle Scholar
• Pincus T, Swearingen C, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patients Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35:2136–47.
   PubMed Web of Science ®Google Scholar
• Yokogawa N, Kaneko T, Nagai Y, Nunokawa T, Sawaki T, Shiroto K, et al. Validation of RAPID3 using a Japanese version of multidimensional health assessment questionnaire with Japanese rheumatoid arthritis patients: characteristics of RAPID3 compared to DAS28 and CDAI. Mod Rheumatol. 2015;25:264–9.
   PubMed Web of Science ®Google Scholar
• Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index 3 (RAPID3), in two abatacept clinical trials; similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology. 2008;47:345–9.
   PubMed Web of Science ®Google Scholar
• Castrejón I, Pincus T, Soubrier, Lin YC, Rat AC, Combe B, et al. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology. 2013;52:1890–7.
   PubMed Web of Science ®Google Scholar
• Pincus T, Swearingen C, Bergman M, Colglazier CL, Kaell A, Kunath A, et al. RAPID3 (routine assessment of patient index data 3) on an MDHAQ (multidimensional health assessment questionnaire): agreement with DAS28 (disease activity score) and CDAI (clinical disease activity index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res. 2010;62:181–9.
   Web of Science ®Google Scholar
• Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64:2814–23.
   PubMed Web of Science ®Google Scholar
• Amett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Riel P, Gribnau EF, Nuver-Zwart I, van de Putte L. Effect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;8646:1036–8.
   Google Scholar
• Svensson B, Andersson MLE, Bala SV, Forslind K, Hafström I, BARFOT study group. Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open. 2013;3:00354.
   Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curis JR, et al. American college of rheumatology 2008 recommendations for use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Vaila C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
   PubMed Web of Science ®Google Scholar
• Singh JR, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–639.
   PubMed Web of Science ®Google Scholar
• Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis. Arthritis rheum. 2001;44:1736–43.
   PubMed Web of Science ®Google Scholar
• Courvoisier N, Dougados M, Chantagrel A, Goupille P, Meyer O, Sibillia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:R106 (doi.10.1186/ar2498).
   Web of Science ®Google Scholar
• Graudal N, Jürgen G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis. Arthritis rheum. 2010;62:2852–63.
   PubMed Web of Science ®Google Scholar